206 related articles for article (PubMed ID: 27863926)
21. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
[TBL] [Abstract][Full Text] [Related]
22. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.
Xia J; Rong L; Sawakami T; Inagaki Y; Song P; Hasegawa K; Sakamoto Y; Tang W
Biomed Pharmacother; 2018 Mar; 99():921-930. PubMed ID: 29710492
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
25. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
26. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
[TBL] [Abstract][Full Text] [Related]
27. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
Lu S; Gao Y; Huang X; Wang X
Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538
[TBL] [Abstract][Full Text] [Related]
28. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
29. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
31. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
32. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
35. Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
World J Gastroenterol; 2007 Apr; 13(13):1989-94. PubMed ID: 17461503
[TBL] [Abstract][Full Text] [Related]
36. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
37. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice.
Liu H; Xu HW; Zhang YZ; Huang Y; Han GQ; Liang TJ; Wei LL; Qin CY; Qin CK
World J Gastroenterol; 2015 Sep; 21(36):10367-74. PubMed ID: 26420963
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
